Treatment of Muscle Weakness in Critically Ill Patients
Primary Purpose
Critical Illness, Respiratory Failure, Myopathy
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sham Treatment
Electrical stimulation
Sponsored by
About this trial
This is an interventional device feasibility trial for Critical Illness focused on measuring ICU Acquired weakness, Critical illness, Mechanical ventilation
Eligibility Criteria
Inclusion Criteria:
- Acute respiratory failure requiring mechanical ventilation
Exclusion Criteria:
- Attending physician on service determines that patient too unstable to tolerate measurements
- Patient requires > 15mcg/min norepinephrine or > 15mg/kg/min of dopamine.
- Fraction of inspired oxygen > 80% or positive end expiratory pressure > 15 cm H20 requirements.
- Cardiac pacemaker or implanted defibrillator.
- Neuromuscular blocking agents delivered within 48 hours of preceding testing.
- Existing neuromuscular disease.
- Profound uncorrectable hypokalemia (< 2.5) OR hypophosphatemia (< 1.0)
- Acute lower extremity deep vein thrombosis
- Pregnancy
- Prisoner
- Institutionalized patient
- If primary attending determines that patient is terminal and will likely have care withdrawn within 7 days
- Do not resuscitate order
- Body mass index > 40
- Patients requiring mechanical ventilation more than 4 days prior to study entry
Sites / Locations
- University of Kentucky Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Sham Comparator
Active Comparator
Arm Label
Sham Treatment
Active Treatment
Arm Description
Sham stimulation twice daily
The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
Outcomes
Primary Outcome Measures
Technical Feasibility, that is ability to complete therapy sessions
Percentage of patients who completed treatment with the device
Secondary Outcome Measures
Total ICU length of stay
Average 7-10 days
Hospital Length of Stay
Average 14-21 days
Functional Status Score for ICU
Average 7-10 days after study entry
Duration of mechanical ventilation after study entry
Average 4-10 days
Change in quadriceps twitch force generation
Quadriceps twitch force generation will be measured using magnetic stimulation of each femoral nerve and compared to measurements obtained at the time of study entry (baseline-prior to randomization)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02247895
Brief Title
Treatment of Muscle Weakness in Critically Ill Patients
Official Title
Effect of Treatment With the Niveus Medical Muscle Stimulation System 110 on Quadriceps Strength In Mechanically Ventilated Patients
Study Type
Interventional
2. Study Status
Record Verification Date
June 2020
Overall Recruitment Status
Terminated
Why Stopped
difficulty meeting enrollment goals
Study Start Date
December 2016 (undefined)
Primary Completion Date
February 2018 (Actual)
Study Completion Date
February 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Gerald Supinski
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients who are admitted to the intensive care unit and require mechanical ventilation frequently develop profound respiratory and limb muscle weakness. Studies show that the development of weakness during the ICU stay results in poor outcomes. Currently there are no treatments for this muscle weakness, but it has been suggested that this weakness might improve with physical therapy. Electrical stimulation is a method to provide direct stimulation to the muscles potentially enhancing function and improving strength. The purpose of this study is to test the hypothesis that neuromuscular electrical stimulation of the quadriceps muscle will improve muscle strength in patients who are critically ill on mechanical ventilation.
Detailed Description
The basic study design is to:
Obtain informed consent from patient or the patients LAR
Randomize subjects to treatment with either:
Sham therapy, consisting of bilateral placement of Niveus Medical Muscle Stimulation System 110 electrodes for 30 minutes twice daily without activation of the electrical circuitry of the unit, or
Active therapy, using the Niveus Medical Muscle Stimulation System 110 electrodes to actively produce a rhythmic quadriceps contraction for 30 minutes twice daily
Measure magnetic stimulated quadriceps twitch (QuadTw) strength bilaterally as well as ultrasound assessment of quadriceps size
Continue sham or active treatment daily for 7 days for a total of 14 sessions
Repeat measurements of magnetic stimulated QuadTw strength and ultrasound assessment of quadriceps size on Day 8 or before Day 8 if the subject is to be discharged from the hospital prior to the allotted duration of sham or active treatment
Functional measurement of the patient using the Functional Status Score for the ICU (FSS-ICU) at the end of the treatment period or upon discharge
A member of the research team will visit the subject until hospital discharge and will record total duration (days) of mechanical ventilation, duration (days) of mechanical ventilation following study entry, duration of ICU stay, ventilator weaning time (days measured from time of first spontaneous breathing trial to extubation), and total duration (days) of hospitalization
The investigators will also review each subject's medical record on entry into the study to obtain demographic information including the following: age, sex, diagnoses, medications, reason for institution of mechanical ventilation, vital signs at the time of the initial visit, bedside parameters of mechanical ventilation use (including mode of ventilation, duration of ventilation, level of oxygen, breath volume and rate, % triggered breaths), most recent arterial blood gas values, and chest radiograph readings at the time of the initial visit. The investigators will also record the subject's weight, BMI and total intake and output values since admission to the ICU. In addition, investigators will monitor each subject's progress in the ICU daily by reviewing the subject's medical record and recording the clinical parameters as well as recording daily weights and total intake and output. These parameters will also be assessed until the time that the patient is discharged from the ICU. In addition, the investigators will record and note all physical therapy and occupational therapy sessions that the subject receives as part of the standard of care in the ICU and in the hospital up until the time of discharge. In the University of Kentucky hospital, occupational therapy records the Barthel Index at each session which uses a scale of 0-100 to assess an individual's functional independence when performing activities of daily living (ADLs). Physical therapy assesses functional status using Kansas University Hospital Physical Therapy Acute Care Functional Outcomes, which also assesses functional status in the categories of bed mobility, transfer, gait and walking distance.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness, Respiratory Failure, Myopathy, Weakness
Keywords
ICU Acquired weakness, Critical illness, Mechanical ventilation
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
2 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sham Treatment
Arm Type
Sham Comparator
Arm Description
Sham stimulation twice daily
Arm Title
Active Treatment
Arm Type
Active Comparator
Arm Description
The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
Intervention Type
Device
Intervention Name(s)
Sham Treatment
Other Intervention Name(s)
Sham treatment without electrical stimulation
Intervention Description
Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
Intervention Type
Device
Intervention Name(s)
Electrical stimulation
Intervention Description
Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
Primary Outcome Measure Information:
Title
Technical Feasibility, that is ability to complete therapy sessions
Description
Percentage of patients who completed treatment with the device
Time Frame
Discharge from ICU, Average 7-10 days
Secondary Outcome Measure Information:
Title
Total ICU length of stay
Description
Average 7-10 days
Time Frame
Discharge from ICU, Average 7-10 days
Title
Hospital Length of Stay
Description
Average 14-21 days
Time Frame
Hospital discharge, Average 14-21 days
Title
Functional Status Score for ICU
Description
Average 7-10 days after study entry
Time Frame
ICU discharge, Average 7-10 days after study entry
Title
Duration of mechanical ventilation after study entry
Description
Average 4-10 days
Time Frame
Until patient is successfully weaned from mechanical ventilation, Average 4-10 days
Title
Change in quadriceps twitch force generation
Description
Quadriceps twitch force generation will be measured using magnetic stimulation of each femoral nerve and compared to measurements obtained at the time of study entry (baseline-prior to randomization)
Time Frame
Baseline (prior to Treatment) and Day 8
Other Pre-specified Outcome Measures:
Title
Rectus Femorus thickness
Description
Rectus femorus thickness will be measured using ultrasound at baseline (study entry) and on Day 8 of study after either sham treatment or neuromuscular stimulation
Time Frame
Day 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Acute respiratory failure requiring mechanical ventilation
Exclusion Criteria:
Attending physician on service determines that patient too unstable to tolerate measurements
Patient requires > 15mcg/min norepinephrine or > 15mg/kg/min of dopamine.
Fraction of inspired oxygen > 80% or positive end expiratory pressure > 15 cm H20 requirements.
Cardiac pacemaker or implanted defibrillator.
Neuromuscular blocking agents delivered within 48 hours of preceding testing.
Existing neuromuscular disease.
Profound uncorrectable hypokalemia (< 2.5) OR hypophosphatemia (< 1.0)
Acute lower extremity deep vein thrombosis
Pregnancy
Prisoner
Institutionalized patient
If primary attending determines that patient is terminal and will likely have care withdrawn within 7 days
Do not resuscitate order
Body mass index > 40
Patients requiring mechanical ventilation more than 4 days prior to study entry
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerald S. Supinski, MD
Organizational Affiliation
Professor of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kentucky Medical Center
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40586
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Treatment of Muscle Weakness in Critically Ill Patients
We'll reach out to this number within 24 hrs